HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced today that it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter financial results for the period ended March 31, 2026, and provide updates on key growth initiatives.
The company plans to share progress on its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and AI programs. These updates come as HeartBeam continues to advance its platform technology, which is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG. The technology received FDA clearance for arrhythmia assessment in December 2024 and for the 12-lead ECG synthesis software in December 2025.
HeartBeam's approach aims to enable portable devices that can be used outside of medical facilities, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care. The company holds over 20 issued patents related to its technology enablement.
Investors and industry observers will be watching the call for details on the commercial launch's early traction and the timeline for broader availability. The development of an extended-wear patch could expand the company's addressable market, while AI programs may enhance diagnostic capabilities. The earnings call will also provide insight into the company's financial health and spending priorities as it scales operations.
For more information, the full press release is available at https://ibn.fm/yN939. The latest news and updates relating to BEAT can be found in the company’s newsroom at https://ibn.fm/BEAT.
Forward-looking statements in the announcement involve risks and uncertainties, including those set forth in the company's SEC filings. The company undertakes no duty to update this information unless required by law.
